Cargando…

Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy

Concurrent chemoradiotherapy with high-dose cisplatin (100 mg/m(2) every 3 weeks) is the preferred regimen with curative intent for patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). This treatment is associated with acute and late toxicities, includin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Porceddu, Sandro V., Scotté, Florian, Aapro, Matti, Salmio, Satu, Castro, Ana, Launay-Vacher, Vincent, Licitra, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987395/ https://www.ncbi.nlm.nih.gov/pubmed/32039012 http://dx.doi.org/10.3389/fonc.2019.01522

Ejemplares similares

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

Evolution of Head and Neck Cutaneous Squamous Cell Carcinoma Nodal Staging—An Australian Perspective
por: Hurrell, Michael J. L., et al.
Publicado: (2022)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Argiris, Athanassios, et al.
Publicado: (2017)

Decitabine Rescues Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma
por: Viet, Chi T., et al.
Publicado: (2014)

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
por: Aapro, Matti, et al.
Publicado: (2022)

Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma
por: Bossi, Paolo, et al.
Publicado: (2016)

The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy
por: Hägerström, Erik, et al.
Publicado: (2019)

Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck.
por: KjellÃ©n, E., et al.
Publicado: (1989)

Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas
por: Griso, Ana Belén, et al.
Publicado: (2022)

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
por: Rades, Dirk, et al.
Publicado: (2023)

Bleeding complications in patients with squamous cell carcinoma of the head and neck
por: Bergamini, Cristiana, et al.
Publicado: (2021)

Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice
por: Falco, Agustín, et al.
Publicado: (2021)

929TiP HERODOTUS: Head and neck cancers international COVID-19 collaboration: An international registry on head and neck cancer with COVID-19
por: Psyrri, A., et al.
Publicado: (2021)

First‐line cetuximab + platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—ENCORE
por: Le Tourneau, Christophe, et al.
Publicado: (2023)

An unsuitable job for a woman /
por: James, P. D.
Publicado: (1983)

Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma
por: Jacinto, Alexandre Arthur, et al.
Publicado: (2018)

Adapting Head and Neck Cancer Management in the Time of COVID-19
por: Mehanna, Hisham, et al.
Publicado: (2020)

MicroRNA-21 induces cisplatin resistance in head and neck squamous cell carcinoma
por: Sheng, Shuyan, et al.
Publicado: (2022)

Eligibility criteria to cisplatin in head and neck squamous cell carcinoma: Egyptian expert opinion
por: Abdulla, Mohamed, et al.
Publicado: (2023)

Transcriptomic and Proteomic Profiles for Elucidating Cisplatin Resistance in Head-and-Neck Squamous Cell Carcinoma
por: Garcia-Mayea, Yoelsis, et al.
Publicado: (2022)

Genetic variability in cisplatin metabolic pathways and outcome of locally advanced head and neck squamous cell carcinoma patients
por: Ferreira, Ana Maria Castro, et al.
Publicado: (2023)

Evaluating the dosimetric effect of treatment-induced changes in virally mediated head and neck cancer patients
por: Brown, Elizabeth, et al.
Publicado: (2013)

Upregulated SLC22A3 has a potential for improving survival of patients with head and neck squamous cell carcinoma receiving cisplatin treatment
por: Hsu, Cheng-Ming, et al.
Publicado: (2017)

Facial nerve perineural spread from cutaneous squamous cell carcinoma of the head and neck: A single institution analysis of epidemiology, treatment, survival outcomes, and prognostic factors
por: Schachtel, Michael J. C., et al.
Publicado: (2022)

Unsuitable for ICU: what happens next?
por: McKeown, A, et al.
Publicado: (2010)

The Unsuitability of White Mice for Studies of Leptospirosis
por: Lahiri, M. N.
Publicado: (1945)

Head and Neck Cancer
por: Psyrri, Amanda, et al.
Publicado: (2009)

DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells
por: Martens-de Kemp, Sanne R., et al.
Publicado: (2013)

Feasibility of Cisplatin/5-Fluorouracil and Panitumumab in Japanese Patients with Squamous Cell Carcinoma of the Head and Neck
por: Tahara, Makoto, et al.
Publicado: (2014)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer
por: Kimura, Takahiro, et al.
Publicado: (2018)

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial
por: Vermorken, J. B., et al.
Publicado: (2014)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development
por: Bonomo, Pierluigi, et al.
Publicado: (2020)

Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review
por: Peddi, Prakash, et al.
Publicado: (2015)

Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
por: Longton, Eleonore, et al.
Publicado: (2018)

Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance
por: Liu, Shutong, et al.
Publicado: (2017)

Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway
por: Yang, Zejia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_285s9imnas0m4d028svgfdulqs